Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fisiopharma s.r.l. - lidocaina - lidocaina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

biesse pharma srl - ceftriaxone - ceftriaxone

Unione Europea - italiano - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel cloridrato - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenti antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Italia - italiano - Ministero della Salute

pharmaidea srl -

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fisiopharma s.r.l. - levulosio 1,6-difosfato - levulosio 1,6-difosfato

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fisiopharma s.r.l. - bupivacaina - bupivacaina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - citalopram - citalopram

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

edmond pharma s.r.l. - repaglinide - repaglinide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - acido zoledronico - acido zoledronico

Unione Europea - italiano - EMA (European Medicines Agency)

mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepilettici, - epilepsypregabalin mylan pharma è indicato come terapia aggiuntiva negli adulti con crisi parziali con o senza secondaria generalizzazione. d'ansia generalizzata disorderpregabalin mylan pharma è indicato per il trattamento del disturbo d'ansia generalizzato (gad) negli adulti.